Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telbivudine for prevention of intrauterine hepatitis B virus transmission
ChiCTR-TCC-09000420Phase 4Completed
- Sponsor
- The Second Hospital of Nanjing
- Start
- Aug 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of telbivudine in hepatitis B (HBV) (2 arms), sponsored by The Second Hospital of Nanjing. Primary endpoints: HBV DNA quantitation and HBV markers, HBsAb quantitation, HBeAg quantitation. Started Aug 2007; status: completed.
02
Drugs
telbivudine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on ChiCTR-TCC-09000420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TCC-09000420.